Nihon Kohden (NHNKY) Projected to Post Quarterly Earnings on Tuesday

Nihon Kohden (OTCMKTS:NHNKY) is expected to be issuing its resultson Tuesday, May 12th. Analysts expect the company to announce earnings of $0.24 per share and revenue of $414.3960 million for the quarter.

Nihon Kohden (OTCMKTS:NHNKY) last announced its quarterly earnings results on Thursday, February 5th. The company reported $0.16 earnings per share (EPS) for the quarter. Nihon Kohden had a net margin of 5.32% and a return on equity of 7.25%. The company had revenue of $362.86 million for the quarter. On average, analysts expect Nihon Kohden to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Nihon Kohden Stock Up 1.3%

Shares of OTCMKTS NHNKY opened at $9.13 on Friday. Nihon Kohden has a twelve month low of $8.93 and a twelve month high of $14.21. The firm has a market cap of $1.56 billion, a P/E ratio of 17.89 and a beta of 0.41. The company has a 50 day moving average of $9.65 and a 200 day moving average of $10.64.

Analyst Ratings Changes

A number of equities analysts recently weighed in on NHNKY shares. UBS Group upgraded shares of Nihon Kohden from a “hold” rating to a “strong-buy” rating in a report on Monday, January 19th. Zacks Research upgraded Nihon Kohden to a “hold” rating in a research note on Monday, April 27th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, Nihon Kohden has an average rating of “Buy”.

About Nihon Kohden

Nihon Kohden Corporation is a Tokyo-based manufacturer of medical electronic equipment, founded in 1951. The company has built a reputation for innovation in patient monitoring and diagnostic systems, developing one of Japan’s earliest electrocardiogram (ECG) machines and pioneering transistor-based oscilloscopes for clinical use. Over the decades, Nihon Kohden has expanded its product portfolio to address a wide range of healthcare needs, from emergency response to intensive care and neurology.

The company’s core offerings include patient monitors, ECG and electroencephalograph (EEG) devices, defibrillators, infusion pumps, and neuromonitoring systems.